If you've been waiting for a sign that the life sciences industry is shaking off its post-pandemic hangover, Thermo Fisher just handed you one.

The scientific instruments and lab supplies giant reported second-quarter results Thursday that beat Wall Street's expectations on both the top and bottom lines. Adjusted earnings came in at $6.03 per share, comfortably above the $5.71 analysts were looking for. Revenue hit $11.994 billion, up 10% from a year ago and ahead of the $11.701 billion consensus. Organic revenue grew 5%.

But the real story isn't just the numbers — it's what the company is saying about the mood of its customers.

Customers Are Finally Feeling Better

On the earnings call, Thermo Fisher noted that customer activity continued to strengthen across all its end markets during the second quarter. That's a big deal because the life sciences sector has been in a bit of a funk since the pandemic boom faded, with customers tightening budgets and delaying purchases.

The improvement showed up across the board. Life Sciences Solutions sales jumped 12.6% to $2.815 billion. Analytical Instruments rose 6.9% to $1.847 billion. Specialty Diagnostics grew 6.3% to $1.205 billion. And the big one — Laboratory Products and Biopharma Services — climbed 11.6% to $6.693 billion.

Digging into the details, the pharma and biotech segment delivered mid-single-digit growth, led by bioproduction and clinical research. The academic and government segment grew low single digits, driven by chromatography and mass spectrometry. The industrial and applied segment also posted mid-single-digit growth.

In other words, it wasn't just one pocket of strength — it was pretty much everywhere.

Raising the Bar for 2026

CEO Marc Casper sounded like a man who's enjoying the view. "It's great to see customer activity continue to strengthen across our end markets," he said. "Our recently closed acquisitions are performing very well, and at the halfway point in the year we're well positioned to deliver a great 2026."

Thermo Fisher raised its full-year adjusted EPS guidance to $24.93-$25.33, up from $24.64-$25.12, and above the consensus estimate of $24.86. The company also nudged its revenue guidance higher, from $47.3 billion-$48.1 billion to $47.40 billion-$48.10 billion. While the range is still 3%-4% growth, Thermo Fisher now expects to deliver at the upper end of that range.

Casper also hinted that the dealmaking isn't over. "We continue to have an active pipeline of M&A opportunities in our highly fragmented industry," he said.

Investors liked what they heard. Shares of Thermo Fisher Scientific (TMO) jumped 9.05% to $574.09 on Thursday.

For a company that makes everything from mass spectrometers to lab pipettes, this earnings report is a strong signal that the life sciences spending cycle is turning. And when Thermo Fisher feels good, the whole industry tends to follow.